Hong Huynh A, Duc Le Hong, Cutting Simon M
School of Biological Sciences, Royal Holloway University of London, Egham, Surrey, UK.
FEMS Microbiol Rev. 2005 Sep;29(4):813-35. doi: 10.1016/j.femsre.2004.12.001. Epub 2004 Dec 16.
The field of probiosis has emerged as a new science with applications in farming and aqaculture as alternatives to antibiotics as well as prophylactics in humans. Probiotics are being developed commercially for both human use, primarily as novel foods or dietary supplements, and in animal feeds for the prevention of gastrointestinal infections, with extensive use in the poultry and aquaculture industries. The impending ban of antibiotics in animal feed, the current concern over the spread of antibiotic resistance genes, the failure to identify new antibiotics and the inherent problems with developing new vaccines make a compelling case for developing alternative prophylactics. Among the large number of probiotic products in use today are bacterial spore formers, mostly of the genus Bacillus. Used primarily in their spore form, these products have been shown to prevent gastrointestinal disorders and the diversity of species used and their applications are astonishing. Understanding the nature of this probiotic effect is complicated, not only because of the complexities of understanding the microbial interactions that occur within the gastrointestinal tract (GIT), but also because Bacillus species are considered allochthonous microorganisms. This review summarizes the commercial applications of Bacillus probiotics. A case will be made that many Bacillus species should not be considered allochthonous microorganisms but, instead, ones that have a bimodal life cycle of growth and sporulation in the environment as well as within the GIT. Specific mechanisms for how Bacillus species can inhibit gastrointestinal infections will be covered, including immunomodulation and the synthesis of antimicrobials. Finally, the safety and licensing issues that affect the use of Bacillus species for commercial development will be summarized, together with evidence showing the growing need to evaluate the safety of individual Bacillus strains as well as species on a case by case by basis.
益生菌领域已成为一门新兴科学,在农业和水产养殖中有着应用,可作为抗生素的替代品,同时也用于人类的预防保健。益生菌正在进行商业化开发,既用于人类,主要作为新型食品或膳食补充剂,也用于动物饲料以预防胃肠道感染,在禽类和水产养殖行业有广泛应用。动物饲料中抗生素即将被禁用,当前对抗生素抗性基因传播的担忧,新抗生素研发的失败以及开发新疫苗存在的固有问题,都使得开发替代预防措施成为一个极具说服力的理由。当今大量使用的益生菌产品中,有细菌芽孢形成菌,大多属于芽孢杆菌属。这些产品主要以芽孢形式使用,已被证明可预防胃肠道疾病,其使用的物种多样性及其应用令人惊讶。理解这种益生菌作用的本质很复杂,不仅因为理解胃肠道内发生的微生物相互作用存在复杂性,还因为芽孢杆菌属被认为是外来微生物。本综述总结了芽孢杆菌益生菌的商业应用。有理由认为,许多芽孢杆菌物种不应被视为外来微生物,而应是在环境以及胃肠道内具有生长和芽孢形成双峰生命周期的微生物。将涵盖芽孢杆菌物种抑制胃肠道感染的具体机制,包括免疫调节和抗菌物质的合成。最后,将总结影响芽孢杆菌物种用于商业开发的安全性和许可问题,以及表明越来越需要逐案评估单个芽孢杆菌菌株以及物种安全性的证据。